CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 661 enrolled
Drug / intervention
Preimplantation Genetic Screening by NGSother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02268786
NCT02268786N/ACompleted

Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment

Illumina, Inc.·interventional·Posted Oct 20, 2014·Updated May 13, 2020

In Brief

A clinical study evaluating Preimplantation Genetic Screening by NGS for Infertility and Aneuploidy. Completed, enrolled 661 participants across 38 sites in 4 countries.

Detailed Summary

The purpose of the current study is to evaluate the effect of preimplantation genetic screening (PGS) by next generation sequencing (NGS) compared to standard morphological assessment of embryos on pregnancy rates through a randomized controlled trial (RCT). All embryos will be vitrified and a single embryo transfer (SET) will be performed with either screened or unscreened embryos depending on randomization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, United Kingdom, United States

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 20, 2014
Enrollment StartSep 1, 2014
Primary CompletionDec 31, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.7 years ago

Interventions

Preimplantation Genetic Screening by NGSother

The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.